// App-Quantinova.ai

547 : Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (ClinicalTrials.gov NCT00002920).

Researchers

Presenter

  • Kathy S. Albain

Principal Investigators

  • Joseph M. Unger

  • Robert B. Livingston

  • Katherine D. Crew

  • Sharon P. Wilczynski

  • Caryl G. Salomon

  • Barbara L. Smith

  • Lucas Wong

  • David Campbell

  • David E. Einspahr

  • Garnet L Anderson

  • Dawn L. Hershman

  • Gary E. Goodman

  • Powel Brown

  • Frank L. Meyskens

  • Ronald Potkul

Medical Centers

  • Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, IL

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Arizona Cancer Center, Tucson, AZ

  • Columbia University Medical Center, New York, NY

  • City of Hope, Duarte, CA

  • Jesse Brown VA Medical Center, Chicago, IL

  • Massachusetts General Hospital, Boston, MA

  • Scott and White Memorial Hospital, Temple, TX

  • Sierra Nevada Memorial Hospital, Grass Valley, CA

  • Stormont-Vail HealthCare Cancer Center, Topeka, KS

  • Swedish Cancer Institute, Seattle, WA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Medroxyprogesterone

  • Tamoxifen

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • NCT00002920

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved